Core Insights - Dongyang Sunshine Pharmaceutical has established a dedicated liver disease team to accelerate the commercialization of innovative hepatitis C drugs [2][3] - The company has received approval for two hepatitis C drugs, Dongweizhuo and Dongyinghe, which are designed for the treatment of chronic hepatitis C virus infections [2][3] - The company is working to reduce its reliance on its flu drug Oseltamivir, which has seen a decline in sales contribution from 81.2% in 2022 to an expected 64.2% in 2024 [2][3] Company Developments - The newly formed liver disease team operates across seven major business areas, including Shanghai, Guangzhou, and Beijing, with a total workforce of over 100 [3] - Dongyang Sunshine Pharmaceutical has three liver disease drugs approved for market, addressing a significant public health issue in China where approximately 10 million people are infected with hepatitis C [3] - The company is attempting to push its hepatitis C drugs into the new round of national medical insurance catalog [4] Market Context - The market for hepatitis C treatments is competitive, with 17 direct-acting antiviral drugs (DAAs) approved in China, eight of which are included in the national medical insurance directory [3] - Dongyang Sunshine Pharmaceutical's ability to succeed in the hepatitis C market will depend on its commercialization capabilities [3]